Evanthia Galanis Selected Research

Complement System Proteins (Complement)

3/2013	Neutralization capacity of measles virus H protein specific IgG determines the balance between antibody-enhanced infectivity and protection in microglial cells.
7/2008	Toxicology study of repeat intracerebral administration of a measles virus derivative producing carcinoembryonic antigen in rhesus macaques in support of a phase I/II clinical trial for patients with recurrent gliomas.

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.

Realize the full power of the drug-disease research graph!

Evanthia Galanis Research Topics

Disease

78	Neoplasms (Cancer) 02/2022 - 02/2002
41	Glioblastoma (Glioblastoma Multiforme) 02/2022 - 04/2005
23	Glioma (Gliomas) 02/2022 - 11/2004
15	Infections 12/2020 - 11/2003
13	Breast Neoplasms (Breast Cancer) 01/2021 - 09/2006
10	Brain Neoplasms (Brain Tumor) 01/2022 - 02/2011
10	Measles 01/2021 - 08/2002
9	Ovarian Neoplasms (Ovarian Cancer) 01/2022 - 08/2002
8	Neoplasm Metastasis (Metastasis) 01/2021 - 09/2009
5	Hematologic Neoplasms (Hematological Malignancy) 10/2018 - 08/2002
4	Oligodendroglioma 01/2022 - 07/2019
4	Melanoma (Melanoma, Malignant) 01/2017 - 02/2002
3	Triple Negative Breast Neoplasms 01/2021 - 09/2014
3	Astrocytoma (Pilocytic Astrocytoma) 07/2019 - 08/2014
3	Fatigue 01/2018 - 07/2009
3	Disease Progression 01/2018 - 04/2008
3	Multiple Myeloma 01/2018 - 07/2009
3	Non-Small-Cell Lung Carcinoma (Carcinoma, Non-Small Cell Lung) 12/2017 - 07/2009
3	Sarcoma (Soft Tissue Sarcoma) 01/2016 - 06/2002
3	Prostatic Neoplasms (Prostate Cancer) 12/2009 - 01/2009
2	Medulloblastoma 01/2022 - 11/2012
2	Thrombocytopenia (Thrombopenia) 01/2018 - 07/2009
2	Head and Neck Neoplasms (Head and Neck Cancer) 01/2018 - 02/2002
2	Communicable Diseases (Infectious Diseases) 01/2016 - 10/2013
2	Chromosomal Instability (Chromosome Stability) 01/2015 - 09/2014
2	Inflammation (Inflammations) 10/2012 - 02/2011
2	Virus Diseases (Viral Diseases) 10/2012 - 10/2012
2	Pleural Effusion (Pleural Effusions) 06/2012 - 08/2010
1	Circulating Neoplastic Cells 01/2022

Drug/Important Bio-Agent (IBA)

16	VaccinesIBA 01/2022 - 08/2002
11	Proteins (Proteins, Gene)FDA Link 12/2020 - 12/2006
10	Pharmaceutical PreparationsIBA 11/2020 - 02/2002
9	Temozolomide (Temodar)FDA LinkGeneric 01/2021 - 10/2011
8	Bevacizumab (Avastin)FDA Link 01/2022 - 09/2009
6	Aurora Kinase AIBA 01/2021 - 05/2013
6	Carcinoembryonic AntigenIBA 01/2018 - 09/2006
5	sodium-iodide symporter (sodium iodide symporter)IBA 01/2018 - 12/2009
5	ErbB Receptors (EGF Receptor)IBA 12/2016 - 04/2005
4	Isocitrate Dehydrogenase (Isocitrate Dehydrogenase (NAD+))IBA 02/2022 - 01/2016
4	AntigensIBA 01/2022 - 10/2012
4	Biomarkers (Surrogate Marker)IBA 01/2019 - 02/2011
4	Vorinostat FDA Link 01/2018 - 04/2009
4	Receptor Protein-Tyrosine Kinases (Tyrosine Kinase Receptors)IBA 01/2016 - 04/2005
4	Phosphotransferases (Kinase)IBA 09/2014 - 08/2005
4	Vascular Endothelial Growth Factor A (Vascular Endothelial Growth Factor)IBA 08/2014 - 09/2009
4	Antineoplastic Agents (Antineoplastics)IBA 09/2009 - 08/2002
3	RNA (Ribonucleic Acid)IBA 10/2018 - 10/2012
3	TOR Serine-Threonine KinasesIBA 01/2018 - 08/2005
3	Peptides (Polypeptides)IBA 01/2017 - 08/2002
3	LigandsIBA 01/2017 - 11/2004
3	Anticonvulsants (Antiepileptic Drugs)IBA 11/2015 - 10/2005
3	EnzymesIBA 11/2015 - 10/2005
3	Irinotecan (Camptosar)FDA LinkGeneric 11/2015 - 10/2003
3	Everolimus FDA Link 09/2015 - 06/2008
3	Interleukin-13IBA 04/2012 - 09/2008
3	Histone Deacetylase InhibitorsIBA 02/2012 - 04/2009
3	Green Fluorescent ProteinsIBA 10/2010 - 12/2006
3	epidermal growth factor receptor VIIIIBA 04/2007 - 12/2006
2	src-Family KinasesIBA 11/2019 - 01/2013
2	Dasatinib (BMS 354825)FDA Link 11/2019 - 01/2013
2	Imatinib Mesylate (Gleevec)FDA Link 07/2019 - 07/2019
2	Dexamethasone (Maxidex)FDA LinkGeneric 01/2019 - 09/2009
2	temsirolimus FDA Link 01/2018 - 08/2005
2	Estrogen Receptor alphaIBA 01/2018 - 01/2014
2	Sorafenib (BAY 43-9006)FDA Link 01/2018 - 09/2013
2	Phenobarbital (Luminal)FDA Link 01/2018 - 09/2014
2	Biological ProductsIBA 01/2017 - 02/2010
2	Heat-Shock Proteins (Heat-Shock Protein)IBA 01/2017 - 01/2017
2	PlatinumIBA 01/2015 - 02/2010
2	Paclitaxel (Taxol)FDA LinkGeneric 01/2015 - 02/2010
2	Hormones (Hormone)IBA 01/2014 - 06/2012
2	Antiviral Agents (Antivirals)IBA 04/2013 - 12/2009
2	AntibodiesIBA 03/2013 - 12/2009
2	Immunoglobulin G (IgG)IBA 03/2013 - 08/2009
2	Complement System Proteins (Complement)IBA 03/2013 - 07/2008
2	Virulence Factors (Pathogenicity Factors)IBA 10/2012 - 02/2011
2	Platinum Compounds (Compounds, Platinum)IBA 10/2012 - 10/2005
2	CytokinesIBA 06/2012 - 02/2011
2	Interleukin-13 Receptors (Interleukin 13 Receptor)IBA 04/2012 - 09/2008
2	Neutralizing AntibodiesIBA 02/2011 - 04/2003
2	Immunoglobulins (Immunoglobulin)IBA 08/2009 - 07/2008
2	dl1520 (ONYX-015)IBA 01/2009 - 04/2003
2	Gemcitabine FDA Link 05/2008 - 06/2002
2	DNA (Deoxyribonucleic Acid)IBA 12/2004 - 04/2003
1	Poly(ADP-ribose) Polymerase InhibitorsIBA 02/2022
1	Permethrin (Ambush)FDA LinkGeneric 01/2022
1	S-(beta-p-methoxypropiophenone)thiamine (MB 2)IBA 01/2022
1	carotuximabIBA 01/2022
1	Small Interfering RNA (siRNA)IBA 01/2022
1	atezolizumabIBA 01/2022
1	Circulating Tumor DNAIBA 01/2022
1	FurinIBA 01/2022
1	Immune Checkpoint InhibitorsIBA 01/2021

Therapy/Procedure

41	Therapeutics 02/2022 - 08/2002
17	Radiotherapy 02/2022 - 12/2007
17	Drug Therapy (Chemotherapy) 01/2021 - 06/2002
12	Immunotherapy 01/2022 - 02/2002
4	Oncolytic Virotherapy 01/2019 - 01/2009
3	Intravenous Administration 10/2012 - 11/2003
2	Injections 01/2009 - 04/2005